Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss
Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss
复制标题
DOI：
10.1093/infdis/jir282
复制
发表时间：
2011-08-01
影响因子：
6.4
通讯作者：
Janssen, Harry L. A.
中科院分区：
文献类型：
--
作者：
Zoutendijk, Roeland;Hansen, Bettina E.;Janssen, Harry L. A.
核苷（酸）类似物可强烈抑制慢性B型肝炎（CH B）感染中的病毒复制，但其对血清B型肝炎表面抗原（HBsAg）水平和HBsAg丢失的长期影响尚不清楚。纳入了75例对ETV或TDF有病毒学应答（VR）的CHB患者。VR后2年HBsAg下降在HBeAg阳性患者中最为明显。年龄、丙氨酸氨基转移酶和HBeAg丢失与HBeAg阳性患者的HBsAg下降相关。HBeAg阳性和HBeAg阴性患者HBsAg丢失的预测中位时间分别为36年和39年。因此，大多数接受ETV和TDF治疗的患者可能需要数十年的治疗才能实现HBsAg丢失。
Nucleos(t)ide analogues strongly inhibit viral replication in chronic hepatitis B (CHB) infection, but knowledge of their long-term effect on serum hepatitis B surface antigen (HBsAg) levels and HBsAg loss is lacking. Seventy-five CHB patients with virological response (VR) to ETV or TDF were included. HBsAg decline 2 years after VR was most pronounced in HBeAg-positive patients. Age, alanine aminotransferase, and HBeAg loss were associated with HBsAg decline in HBeAg-positive patients. Predicted median time to HBsAg loss was 36 years for HBeAg-positive and 39 years for HBeAg-negative patients. Thus, most patients treated with ETV and TDF will probably need decades of therapy to achieve HBsAg loss.